Navigation Links
Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease
Date:10/30/2009

Pasadena, Calif.Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

"Gene therapy in these models successfully attenuated the symptoms of Huntington's disease and increased life span," notes Paul Patterson, the Anne P. and Benjamin F. Biaggini Professor of Biological Sciences.

Patterson is the senior investigator on the study, which was published in the October 28 issue of the Journal of Neuroscience.

Huntington's disease is a neurodegenerative disorder with a genetic basis. The disorder has its roots in a mutation in a protein called huntingtin, or Htt. (The gene itself is also referred to as the huntingtin gene.)

All versions of the Htt gene have repeats of a particular trio of nucleotidesspecifically, C, A, and G, which together code for the amino acid glutamine. In most people, that trio is repeated between 10 and 35 times. But in people who develop Huntington's disease, that genetic stutter goes on and on; they will have anywhere between 36 to upwards of 120 repeats.

The result of all these repeats? An abnormally long version of the Htt protein, which gets chopped up into smaller, toxic pieces and accumulates in nerve cells, debilitating them.

Enter Patterson group members Amber Southwell and Jan Ko, who began to look at the efficacy of two different intrabodies that had been shown, in cell cultures and fruit-fly models, to reduce the accumulation of toxic Htt protein. To see whether those effects would hold true in mammalian systems as well, the team tested the intrabodies in a series of five different mouse models of Huntington's.

One of the two intrabodies had some negative results, actually increasing Huntington's-related mortality in one model.

But the other intra
'/>"/>

Contact: Lori Oliwenstein
lorio@caltech.edu
626-395-3631
California Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Caltech scientists create robot surrogate for blind persons in testing visual prostheses
2. Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells
3. Caltech neuroscientists find brain region responsible for our sense of personal space
4. Caltech researchers explore how cells reconcile mixed messages in decisions about growth
5. Caltech scientists reveal how neuronal activity is timed in brains memory-making circuits
6. Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
7. Caltech scientists control complex nucleation processes using DNA origami seeds
8. Caltech researchers train computers to analyze fruit-fly behavior
9. Caltech and UCSD researchers shed light on how proteins find their shapes
10. Caltech researchers help unlock the secrets of gene regulatory networks
11. Caltech researchers get first look at how groups of cells coordinate their movements
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How nutrition affects healthy aging 2Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 1Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 2Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 3Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 4Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records 28EHRs 29 53831 5Bellicum Pharmaceuticals Announces Initiation of Phase I II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 53826 1Bellicum Pharmaceuticals Announces Initiation of Phase I II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 53826 2Bellicum Pharmaceuticals Announces Initiation of Phase I II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 53826 3Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results 13409 1